Y-Mabs Therapeutics | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 19.53 M

Revenue: As of FY2025 Q2, the actual value is USD 19.53 M, beating the estimate of USD 18.4 M.

EPS: As of FY2025 Q2, the actual value is USD -0.07, beating the estimate of USD -0.2625.

EBIT: As of FY2025 Q2, the actual value is USD -5.604 M.

Segment Revenue

• Total revenues for the quarter ended June 30, 2025, were $19.5 million, a 14% decrease from $22.8 million in the same period in 2024. This decrease was driven by a $2.9 million decrease in Ex-U.S. DANYELZA net product revenues and a $0.9 million decrease in U.S. DANYELZA net product revenues, partially offset by a $0.5 million increase in license revenue.

Operational Metrics

• Gross profit for the quarter ended June 30, 2025, was $16.8 million, compared to $19.8 million for the same period in 2024, with gross margins of 86% and 87%, respectively.
• Research and development expenses decreased to $11.1 million from $12.3 million for the quarter ended June 30, 2024.
• Selling, general, and administrative expenses were $11.3 million, down from $17.2 million in the same period in 2024.
• Net loss for the quarter ended June 30, 2025, was $3.2 million, compared to a net loss of $9.2 million for the same period in 2024.

Cash Flow

• As of June 30, 2025, cash and cash equivalents were $62.3 million.
• Net cash used in operating activities for the six months ended June 30, 2025, was $5.3 million, compared to $3.2 million for the same period in 2024.

Unique Metrics

• The company recognized $0.5 million in license revenue during the three months ended June 30, 2025, related to sales-based milestone achievements by a partner in Israel.

Outlook / Guidance

• Y-mAbs announced a definitive agreement for acquisition by SERB Pharmaceuticals valued at $412.0 million, expected to close by the fourth quarter of 2025, subject to customary conditions.